While Centessa Pharmaceuticals plc ADR has underperformed by -0.07%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CNTA rose by 53.70%, with highs and lows ranging from $19.09 to $7.75, whereas the simple moving average fell by -8.77% in the last 200 days.
On March 31, 2025, Piper Sandler started tracking Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) recommending Overweight. A report published by TD Cowen on January 07, 2025, Initiated its previous ‘Buy’ rating for CNTA. Morgan Stanley also Upgraded CNTA shares as ‘Overweight’, setting a target price of $26 on the company’s shares in a report dated September 20, 2024. B. Riley Securities Initiated an Buy rating on September 19, 2024, and assigned a price target of $33. Oppenheimer initiated its ‘Outperform’ rating for CNTA, as published in its report on July 18, 2024. Jefferies’s report from November 15, 2023 suggests a price prediction of $11 for CNTA shares, giving the stock a ‘Buy’ rating. Morgan Stanley also rated the stock as ‘Equal-Weight’.
Analysis of Centessa Pharmaceuticals plc ADR (CNTA)
Further, the quarter-over-quarter decrease in sales is -100.00%, showing a negative trend in the upcoming months.
Centessa Pharmaceuticals plc ADR’s future performance can be predicted by a variety of well-rounded types of analysis and research, with equity being one of the most crucial ones. The goal here is to ensure that your current return on equity of -73.75% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 9.25, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can be an extremely valuable indicator of volatility, and CNTA is registering an average volume of 1.02M. On a monthly basis, the volatility of the stock is set at 8.66%, whereas on a weekly basis, it is put at 4.64%, with a gain of 5.22% over the past seven days. Furthermore, long-term investors anticipate a median target price of $31.75, showing growth from the present price of $13.71, which can serve as yet another indication of whether CNTA is worth investing in or should be passed over.
How Do You Analyze Centessa Pharmaceuticals plc ADR Shares?
Besides checking the fundamentals, you should also know how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 36.45%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 54.91% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
CNTA shares are owned by institutional investors to the tune of 54.91% at present.
